PUBLISHER: The Business Research Company | PRODUCT CODE: 1949799
PUBLISHER: The Business Research Company | PRODUCT CODE: 1949799
Aurora Kinase B Global Market Report 2026
Aurora kinase B is a protein enzyme that plays a critical role in cell division, particularly during mitosis. It regulates chromosome alignment, segregation, and the proper distribution of genetic material to daughter cells. Aurora kinase B is essential for maintaining genomic stability, and its dysregulation is often linked to various cancers.
The main types of Aurora kinase B inhibitors include AZD-2811, CS-2164, danusertib, ilorasertib, NMI-900, and others. AZD-2811 is a nanoparticle formulation of a potent Aurora kinase B inhibitor, designed for the treatment of solid tumors and hematologic malignancies. It is used for conditions such as anaplastic large cell lymphoma, kidney cancer, lung cancer, prostate cancer, and others. This drug is utilized by various end-users, including hospitals, research institutes, diagnostic laboratories, and other healthcare settings.
Tariffs are influencing the aurora kinase b market by increasing costs of imported active pharmaceutical ingredients, laboratory reagents, bioprocessing equipment, and analytical instruments used in drug discovery and clinical development. Research institutes and pharmaceutical developers in North America and Europe are most affected due to reliance on specialized imported inputs, while Asia-Pacific faces higher costs for exporting investigational compounds. These tariffs are extending development timelines and increasing R&D expenditures. At the same time, they are encouraging localized API manufacturing, regional research collaborations, and domestic capacity building in advanced oncology drug development.
The aurora kinase b market research report is one of a series of new reports from The Business Research Company that provides aurora kinase b market statistics, including aurora kinase b industry global market size, regional shares, competitors with a aurora kinase b market share, detailed aurora kinase b market segments, market trends and opportunities, and any further data you may need to thrive in the aurora kinase b industry. This aurora kinase b market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The aurora kinase b market size has grown rapidly in recent years. It will grow from $1.27 billion in 2025 to $1.43 billion in 2026 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to advancements in molecular oncology research, identification of aurora kinase b as a cancer target, expansion of clinical trial infrastructure, increasing investment in targeted cancer therapies, progress in kinase inhibitor development.
The aurora kinase b market size is expected to see rapid growth in the next few years. It will grow to $2.22 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to increasing demand for precision cancer therapeutics, expansion of personalized medicine approaches, rising oncology clinical trial activity, growing investments in novel kinase inhibitors, improved regulatory support for targeted oncology drugs. Major trends in the forecast period include increasing development of selective aurora kinase b inhibitors, growing emphasis on combination oncology therapies, expansion of precision oncology drug pipelines, rising focus on mitotic targeted therapies, improved biomarker-based patient stratification.
The rising incidence of cancer is expected to accelerate the growth of the aurora kinase B market. Cancer is a group of diseases characterized by uncontrolled cell growth, which can spread to surrounding tissues and metastasize to other parts of the body. Factors such as an aging population, lifestyle changes, environmental exposures, and improved detection are contributing to the increase in cancer cases. Aurora kinase B plays a crucial role in mitosis, and its overexpression is linked to chromosomal instability and cancer progression, making it a key target for cancer therapies. For example, in February 2024, the World Health Organization (WHO) estimated that 20 million new cancer cases were reported globally in 2022, along with 9.7 million deaths. By 2050, the number of new cancer cases is expected to surpass 35 million, reflecting a 77% increase from 2022. Therefore, the increasing cancer incidence is driving the growth of the aurora kinase B market.
Leading companies in the aurora kinase B market are developing innovative products, such as aurora kinase inhibitors, to specifically target and disrupt cell division processes. These inhibitors aim to block the activity of aurora kinases, which are critical for cell division, thus potentially reducing tumor growth. For example, in June 2023, Ellipses Pharma, a UK-based biotechnology company, received FDA approval for EP0042, a dual FLT-3 and aurora kinase inhibitor. EP0042 is being developed as a treatment for acute myeloid leukemia (AML), targeting both FLT3 and aurora kinase. This approach aims to treat AML patients who have developed resistance to FLT3 inhibitors, with research showing that dual inhibition can overcome resistance both in vitro and in vivo.
In June 2024, Gedeon Richter Plc., a Hungary-based pharmaceutical company, acquired BCI Pharma for $13.3 million. This acquisition strengthens Richter's ability to develop targeted treatments in oncology and other therapeutic areas, as BCI Pharma is a Belgium-based manufacturer of aurora kinase B inhibitors.
Major companies operating in the aurora kinase b market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc
North America was the largest region in the aurora kinase B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the aurora kinase b market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The aurora kinase B market consists of sales of aurora kinase B inhibitors, antibodies, diagnostic kits, assay kits, and recombinant proteins. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Aurora Kinase B Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses aurora kinase b market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for aurora kinase b ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The aurora kinase b market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
- Markets Covered:1) By Type: AZD-2811; CS-2164; Danusertib; Ilorasertib; NMI-900; Other Types
- 2) By Application: Anaplastic Large Cell Lymphoma; Kidney Cancer; Lung Cancer; Prostate Cancer; Other Applications
- 3) By End-User: Hospitals; Research Institutes; Diagnostic Laboratories; Other End-Users
- Subsegments:
- 1) By AZD-2811: Phase I Clinical Trials AZD-2811; Preclinical Development of AZD-2811; AZD-2811 in Combination Therapy; Targeted Cancer Treatment with AZD-2811
- 2) By CS-2164: Phase II Clinical Trials CS-2164; Preclinical Development of CS-2164; CS-2164 in Targeted Cancer Therapy; CS-2164 Combination Therapy in Clinical Studies
- 3) By Danusertib: Phase III Clinical Trials Danusertib; Danusertib for Hematological Malignancies; Danusertib for Solid Tumors; Combination Therapy with Danusertib
- 4) By Ilorasertib: Preclinical Development of Ilorasertib; Ilorasertib in Solid Tumor Treatment; Phase I and II Clinical Trials of Ilorasertib; Ilorasertib in Combination with Chemotherapies
- 5) By NMI-900: NMI-900 in Early-Stage Clinical Trials; NMI-900 for Targeted Cancer Therapy; Preclinical Studies of NMI-900; NMI-900 Combination Therapy Trials
- 6) By Other Types: Other Aurora Kinase B Inhibitors in Development; Novel Targeted Aurora Kinase B Drugs; Combination Therapies Involving Aurora Kinase B Inhibitors; Investigational Aurora Kinase B Inhibitors in Oncology
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.; Sanofi SA; Bristol-Myers Squibb Company; AstraZeneca PLC; Novartis AG; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Boehringer Ingelheim International GmbH; Amgen Inc.; Astellas Pharma Inc.; Promega Corporation; Rigel Pharmaceuticals Inc.; Tocris Bioscience; BPS Bioscience Inc.; Advenchen Laboratories LLC; Shenzhen Chipscreen Biosciences Co. Ltd.; Cyclacel Pharmaceuticals Inc.; Sareum Holdings plc
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: Word, PDF or Interactive Report
- + Excel Dashboard
- Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
Table of Contents
1. Executive Summary
- 1.1. Key Market Insights (2020-2035)
- 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
- 1.3. Major Factors Driving the Market
- 1.4. Top Three Trends Shaping the Market
2. Aurora Kinase B Market Characteristics
- 2.1. Market Definition & Scope
- 2.2. Market Segmentations
- 2.3. Overview of Key Products and Services
- 2.4. Global Aurora Kinase B Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
- Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
- 2.4.4. Market Attractiveness Scoring and Interpretation
- 2.4.5. Strategic Implications and Recommendations
3. Aurora Kinase B Market Supply Chain Analysis
- 3.1. Overview of the Supply Chain and Ecosystem
- 3.2. List Of Key Raw Materials, Resources & Suppliers
- 3.3. List Of Major Distributors and Channel Partners
- 3.4. List Of Major End Users
4. Global Aurora Kinase B Market Trends And Strategies
- 4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Industry 4.0 & Intelligent Manufacturing
- 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.5 Sustainability, Climate Tech & Circular Economy
- 4.2. Major Trends
- 4.2.1 Increasing Development Of Selective Aurora Kinase B Inhibitors
- 4.2.2 Growing Emphasis On Combination Oncology Therapies
- 4.2.3 Expansion Of Precision Oncology Drug Pipelines
- 4.2.4 Rising Focus On Mitotic Targeted Therapies
- 4.2.5 Improved Biomarker-Based Patient Stratification
5. Aurora Kinase B Market Analysis Of End Use Industries
- 5.1 Hospitals
- 5.2 Research Institutes
- 5.3 Diagnostic Laboratories
- 5.4 Oncology Specialty Clinics
- 5.5 Pharmaceutical Companies
6. Aurora Kinase B Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Aurora Kinase B Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
- 7.1. Global Aurora Kinase B PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 7.2. Global Aurora Kinase B Market Size, Comparisons And Growth Rate Analysis
- 7.3. Global Aurora Kinase B Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
- 7.4. Global Aurora Kinase B Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Aurora Kinase B Total Addressable Market (TAM) Analysis for the Market
- 8.1. Definition and Scope of Total Addressable Market (TAM)
- 8.2. Methodology and Assumptions
- 8.3. Global Total Addressable Market (TAM) Estimation
- 8.4. TAM vs. Current Market Size Analysis
- 8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Aurora Kinase B Market Segmentation
- 9.1. Global Aurora Kinase B Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types
- 9.2. Global Aurora Kinase B Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications
- 9.3. Global Aurora Kinase B Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users
- 9.4. Global Aurora Kinase B Market, Sub-Segmentation Of AZD-2811, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811
- 9.5. Global Aurora Kinase B Market, Sub-Segmentation Of CS-2164, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies
- 9.6. Global Aurora Kinase B Market, Sub-Segmentation Of Danusertib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib
- 9.7. Global Aurora Kinase B Market, Sub-Segmentation Of Ilorasertib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies
- 9.8. Global Aurora Kinase B Market, Sub-Segmentation Of NMI-900, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials
- 9.9. Global Aurora Kinase B Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology
10. Aurora Kinase B Market Regional And Country Analysis
- 10.1. Global Aurora Kinase B Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- 10.2. Global Aurora Kinase B Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Aurora Kinase B Market
- 11.1. Asia-Pacific Aurora Kinase B Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 11.2. Asia-Pacific Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Aurora Kinase B Market
- 12.1. China Aurora Kinase B Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 12.2. China Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Aurora Kinase B Market
- 13.1. India Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Aurora Kinase B Market
- 14.1. Japan Aurora Kinase B Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 14.2. Japan Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Aurora Kinase B Market
- 15.1. Australia Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Aurora Kinase B Market
- 16.1. Indonesia Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Aurora Kinase B Market
- 17.1. South Korea Aurora Kinase B Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 17.2. South Korea Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Aurora Kinase B Market
- 18.1. Taiwan Aurora Kinase B Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 18.2. Taiwan Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Aurora Kinase B Market
- 19.1. South East Asia Aurora Kinase B Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 19.2. South East Asia Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Aurora Kinase B Market
- 20.1. Western Europe Aurora Kinase B Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 20.2. Western Europe Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Aurora Kinase B Market
- 21.1. UK Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Aurora Kinase B Market
- 22.1. Germany Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Aurora Kinase B Market
- 23.1. France Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Aurora Kinase B Market
- 24.1. Italy Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Aurora Kinase B Market
- 25.1. Spain Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Aurora Kinase B Market
- 26.1. Eastern Europe Aurora Kinase B Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 26.2. Eastern Europe Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Aurora Kinase B Market
- 27.1. Russia Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Aurora Kinase B Market
- 28.1. North America Aurora Kinase B Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 28.2. North America Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Aurora Kinase B Market
- 29.1. USA Aurora Kinase B Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 29.2. USA Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Aurora Kinase B Market
- 30.1. Canada Aurora Kinase B Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 30.2. Canada Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Aurora Kinase B Market
- 31.1. South America Aurora Kinase B Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 31.2. South America Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Aurora Kinase B Market
- 32.1. Brazil Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Aurora Kinase B Market
- 33.1. Middle East Aurora Kinase B Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 33.2. Middle East Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Aurora Kinase B Market
- 34.1. Africa Aurora Kinase B Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 34.2. Africa Aurora Kinase B Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Aurora Kinase B Market Regulatory and Investment Landscape
36. Aurora Kinase B Market Competitive Landscape And Company Profiles
- 36.1. Aurora Kinase B Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
- 36.2. Aurora Kinase B Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
- 36.3. Aurora Kinase B Market Company Profiles
- 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
37. Aurora Kinase B Market Other Major And Innovative Companies
- Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd.
38. Global Aurora Kinase B Market Competitive Benchmarking And Dashboard
39. Key Mergers And Acquisitions In The Aurora Kinase B Market
40. Aurora Kinase B Market High Potential Countries, Segments and Strategies
- 40.1 Aurora Kinase B Market In 2030 - Countries Offering Most New Opportunities
- 40.2 Aurora Kinase B Market In 2030 - Segments Offering Most New Opportunities
- 40.3 Aurora Kinase B Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies
41. Appendix
- 41.1. Abbreviations
- 41.2. Currencies
- 41.3. Historic And Forecast Inflation Rates
- 41.4. Research Inquiries
- 41.5. The Business Research Company
- 41.6. Copyright And Disclaimer
